CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a global leader in life sciences, today announced the availability of E-Gel® CloneWell™ SYBR® gels, the newest addition to the company’s patented E-Gel® line of products. These gels provide a fast and convenient way to obtain improved cloning efficiency without exposing the user to harmful UV trans-illumination.
